Baxter International Inc. completed a strategic divestiture of its Kidney Care business to Carlyle Group for approximately $3.4 billion, positioning itself for enhanced operational focus and growth in the medtech sector.

Information on the Target

Baxter International Inc. (NYSE:BAX) is a prominent player in the global medtech industry, committed to enhancing patient care through innovative medical products. Headquartered in Deerfield, Illinois, Baxter specializes in a diverse range of medical technologies crucial for clinical and surgical settings. The company recently made headlines with its strategic decision to divest its Kidney Care business, which has been integral to its portfolio, in a move to streamline operations and focus on core competencies.

As of the end of 2024, Baxter reported worldwide sales from continuing operations totaling approximately $10.64 billion. The fourth quarter contributed significantly, with sales nearing $2.75 billion, showcasing resilience amidst market challenges. This financial strength positions Baxter effectively for future growth and innovation.

Industry Overview in the U.S.

The medtech industry in the United States is a robust sector characterized by rapid technological advancements and increasing demand for healthcare solutions. As a leader within this space, Baxter op